FDA Approves Tebentafusp-tebn in Adult HLA-A*02:01-Positive Unresectable/Metastatic Uveal Melanoma
January 26th 2022Tebentafusp-tebn has been granted FDA approval to treat HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma based on positive results from a phase 3 study.
Read More
Doctors Debate: Should Stage III Melanoma Be Treated in the Adjuvant or Neoadjuvant Setting?
January 20th 2022During a recent medical meeting, Michael Lowe, MD, MA, FACS, FSSO, and Ragini Kudchadkar, MD, debated adjuvant therapy versus neoadjuvant for the treatment of resectable stage III melanoma.
Read More
Nivolumab/Relatlimab Combo Improves PFS in Advanced Melanoma
January 6th 2022Efficacy was seen with blocking LAG-3 in combination with PD-1 as a therapeutic strategy for patients with melanoma. Additionally, this research establishes LAG-3 as the third immune checkpoint pathway to have proven clinical benefit in this patient population.
Read More
Darovasertib/Crizotinib Shows Early Efficacy in Metastatic Uveal Melanoma
December 10th 2021Darovasertib and crizotinib demonstrated promising efficacy and tolerable safety in patients with metastatic uveal melanoma, according to preliminary results of a phase 1/2 trial announced in a press release from IDEAYA Biosciences.
Read More
Second-Line Cemiplimab Improves Survival and Quality of Life in Cervical Squamous Cell Carcinoma
October 5th 2021Results from the EMPOWER-Cervical 1/ GOG-3016/ENGOT-cx9 trial led the FDA to grant priority review to cemiplimab as treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.
Read More
Risk Information Can Influence Clinical Decision-Making in Melanoma
July 27th 2021Cutaneous melanoma is disproportionately lethal among skin cancers, and as incidence rates of cutaneous melanoma continue to rise in the United States, so does the importance of managing melanoma cases in alignment with personalized prognoses.
Read More
FDA Expands Label for Pembrolizumab to Include Treatment of Locally Advanced cSCC
July 6th 2021The FDA has expanded its approval for pembrolizumab monotherapy to include the treatment of patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation.
Read More
Increased Responses to Lifileucel Plus Pembrolizumab Observed in Patients With Advanced Melanoma
June 4th 2021In patients with pre-immune checkpoint inhibitor-naïve advanced melanoma, treatment with the combination of lifileucel plus pembrolizumab, compared to pembrolizumab alone, increased the overall response rate.
Read More
Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma
April 10th 2021In patient with metastatic uveal melanoma, frontline treatment with tebentafusp achieved significant and clinically meaningful improvement in overall survival, according to data from the phase 3 IMCgp100-202 trial.
Read More
Experts Contemplate Realistic Treatment Goals Using Hedgehog Inhibitors in Basal Cell Carcinoma
March 26th 2021Hedgehog inhibitors are becoming more widely used for Basal cell carcinoma. Two experts, Shailender Bhatia, MD and Paul T. Nghiem, MD, PhD discussed the reality of hedgehog inhibitor use in practice during a virtual Targeted Oncology Case-Based Roundtable event.
Read More